Two-pronged immune evasion of pseudouridine-modified RNA.

IF 13.8 1区医学 Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

Trends in molecular medicine Pub Date : 2025-10-01 Epub Date: 2025-09-10 DOI:10.1016/j.molmed.2025.08.007

Jonas Cerneckis, Yanhong Shi

引用次数: 0

Abstract

It is well established that pseudouridine (Ψ) and its derivative N¹-methylpseudouridine (m¹Ψ) suppress unwanted immunogenicity of RNA-based therapeutics. However, molecular mechanisms governing such immune evasion remain elusive. In a recent article, Bérouti, Wagner, and colleagues show that Ψ impairs the processing of Toll-like receptor (TLR)-agonistic ligands and hinders TLR activation.

查看原文本刊更多论文

假尿嘧啶修饰RNA的双重免疫逃避。

假尿嘧啶（Ψ）及其衍生物n1 -甲基假尿嘧啶（m1Ψ）可以抑制基于rna的治疗方法的不良免疫原性。然而，控制这种免疫逃避的分子机制仍然难以捉摸。在最近的一篇文章中，b routi， Wagner和同事们表明Ψ损害toll样受体(TLR)-激动性配体的加工并阻碍TLR的激活。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Trends in molecular medicine 医学-生化与分子生物学

CiteScore

24.60

自引率

0.00%

发文量

142

审稿时长

6-12 weeks

期刊介绍： Trends in Molecular Medicine (TMM) aims to offer concise and contextualized perspectives on the latest research advancing biomedical science toward better diagnosis, treatment, and prevention of human diseases. It focuses on research at the intersection of basic biology and clinical research, covering new concepts in human biology and pathology with clear implications for diagnostics and therapy. TMM reviews bridge the gap between bench and bedside, discussing research from preclinical studies to patient-enrolled trials. The major themes include disease mechanisms, tools and technologies, diagnostics, and therapeutics, with a preference for articles relevant to multiple themes. TMM serves as a platform for discussion, pushing traditional boundaries and fostering collaboration between scientists and clinicians. The journal seeks to publish provocative and authoritative articles that are also accessible to a broad audience, inspiring new directions in molecular medicine to enhance human health.